CIFR
Cipher Mining Inc.
There isn't enough reported data to score CIFR yet.
PACS
PACS Group, Inc.
PACS's fundamentals are strong: earnings per share grew 73% and revenue grew 11%. At 27x earnings, it's trading above its usual 25x. Analysts expect that strong growth to continue.
CIFR Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| N/A | |
| N/A |
CIFR's revenue and profitability are currently weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like CIFR.
PACS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| N/A | |
| N/A |
PACS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like PACS.
CIFR PE Valuation
CIFR has no meaningful PE right now: it lost money over the past year.
PACS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $30.55 | -36% |
| Forward | 18x | $48.00 | — |
| Fair | 24x | $43.08 | -10% |
| Current | 27x | $48.00 | — |
| Expensive | 34x | $60.12 | +25% |
Historical ranges are pointers, not guarantees.
PACS's PE is in its fair range at 27x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CIFR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect CIFR's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
PACS Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for PACS, with profitability improving.
CIFR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.06 | -$2.86 |
| Q2 2026 | -$2.85 | -$2.40 |
| Q1 2026 | -$2.32 | -$1.94 |
| Q4 2025 | -$2.15 | -$2.01 |
| Q3 2025 | -$0.20 | -$0.07 |
| Q2 2025 | -$0.45 | -850% |
| Q1 2025 | -$0.38 | -733% |
| Q4 2024 | -$0.14 | -$0.04 |
CIFR lost $3.06 per share over the past year, and its loss has widened in each of the last four quarters.
PACS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.64 | +50% |
| Q3 2026 | $1.76 | +73% |
| Q2 2026 | $1.71 | +114% |
| Q1 2026 | $1.55 | +269% |
| Q4 2025 | $1.22 | +94% |
| Q3 2025 | $1.02 | +59% |
| Q2 2025 | $0.80 | +19% |
| Q1 2025 | $0.42 | -52% |
| Q4 2024 | $0.63 | -16% |
PACS has the edge over CIFR on earnings quality, reporting a profit while its opponent remains loss making.
CIFR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $26.7M | -63% |
| Q2 2026 | $24.8M | -43% |
| Q1 2026 | $34.8M | -29% |
| Q4 2025 | $59.7M | +41% |
| Q3 2025 | $71.7M | +198% |
| Q2 2025 | $43.6M | +18% |
| Q1 2025 | $49M | +1.7% |
| Q4 2024 | $42.2M | -2.8% |
CIFR's revenue has slid since its 2025 peak: $27M last quarter, down 63% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -269% | -217 points |
| Q2 2026 | -316% | -212 points |
| Q1 2026 | -329% | -251 points |
| Q4 2025 | -503% | -544 points |
| Q3 2025 | -52% | +327 points |
| Q2 2025 | -104% | -60 points |
| Q1 2025 | -78% | -175 points |
| Q4 2024 | 40% | +4 points |
CIFR's operating margin was −269% last quarter, down 217 points from the same quarter a year ago.
PACS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +11% |
| Q2 2026 | $1.4B | +9.1% |
| Q1 2026 | $1.4B | +11% |
| Q4 2025 | $1.4B | +12% |
| Q3 2025 | $1.3B | +31% |
| Q2 2025 | $1.3B | +33% |
| Q1 2025 | $1.3B | +37% |
| Q4 2024 | $1.2B | +42% |
PACS has the edge over CIFR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.7% | +0.2 points |
| Q2 2026 | 7.7% | +1.5 points |
| Q1 2026 | 8.4% | +4.7 points |
| Q4 2025 | 7% | +1 points |
| Q3 2025 | 6.4% | +4.2 points |
| Q2 2025 | 6.2% | +6.1 points |
| Q1 2025 | 3.8% | -4.8 points |
| Q4 2024 | 6% | -6 points |
PACS has the edge over CIFR on profitability, with a higher operating margin.
CIFR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.7B | -$1.4B |
| Q2 2026 | -$653.8M | -$566.3M |
| Q1 2026 | -$462.5M | -$390.7M |
| Q4 2025 | -$280.3M | -$204.2M |
| Q3 2025 | -$256.2M | -$173.1M |
| Q2 2025 | -$87.5M | -$54.3M |
| Q1 2025 | -$71.8M | -$37.3M |
| Q4 2024 | -$76.1M | +$38M |
CIFR's free cash flow was −$3.1B over the past year, against −$492M the year before. Free cash flow isn't a meaningful measure for financial services companies like CIFR.
PACS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $178.7M | -4.3% |
| Q2 2026 | $109M | +221% |
| Q1 2026 | $214.5M | +62% |
| Q4 2025 | -$54.5M | -236% |
| Q3 2025 | $186.8M | -3.4% |
| Q2 2025 | $34M | +75% |
| Q1 2025 | $132.5M | +176% |
| Q4 2024 | $40M | +$64.9M |
PACS has the edge over CIFR on cash generation, producing positive trailing cash flow while its opponent burns cash.
CIFR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.4% | +30.3M shares |
| 1 year | +12% | +46.5M shares |
| 3 years | +75% | +188M shares |
| 5 years | +102% | +222M shares |
CIFR has 440M diluted shares, up 12% from a year ago, despite $151M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7M |
| Q2 2026 | $45.2M |
| Q1 2026 | $3.8M |
| Q4 2025 | $82.3M |
| Q3 2025 | $3M |
| Q2 2025 | $3.2M |
| Q1 2025 | $1.1M |
| Q4 2024 | $16.9M |
CIFR spent $151M buying back its own shares over the past year, about six times what it spent the year before.
PACS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.9M shares |
| 1 year | -0.5% | -794K shares |
| 3 years | +7.6% | +11.5M shares |
PACS has the edge over CIFR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
CIFR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -2.3x | Net Cash |
| Q1 2025 | 125.4x | High |
| Q4 2024 | 0.5x | Very low |
| Q3 2024 | -0.7x | Net Cash |
| Q2 2024 | -1.2x | Net Cash |
| Q1 2024 | -0.9x | Net Cash |
| Q4 2023 | -2.2x | Net Cash |
| Q2 2023 | -0.1x | Net Cash |
CIFR has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like CIFR.
PACS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | 0.9x | Very low |
| Q2 2024 | 0.7x | Very low |
| Q1 2024 | 0.6x | Very low |
| Q4 2023 | 10.2x | High |
PACS's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like PACS.
CIFR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.4 | Neutral |
| Stochastic | 7.8 | Oversold |
CIFR's weekly RSI is 34 (neutral) and its Stochastic is 8 (oversold).
PACS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.3 | Neutral |
| Stochastic | 75.8 | Neutral |
PACS's weekly RSI is 62 (neutral) and its Stochastic is 76 (neutral).
CIFR PE vs Financial Services Sector
| Metric | CIFR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
CIFR has no meaningful PE right now: it lost money over the past year.
PACS PE vs Financial Services Sector
| Metric | PACS | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 13x | 109% above |
| PE % | 63 | 30 | 33 pts above |
PACS is trading at 27x earnings, a 109% premium to the Financial Services sector's median of 13x.
CIFR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.6 | 33% below |
| 20 week MA | $15.5 | 54% below |
| 50 week MA | $17.0 | 58% below |
| 100 week MA | $12.2 | 41% below |
| 200 week MA | $7.86 | 9% below |
PACS has stronger trend alignment. CIFR is above 0 of 5 weekly averages versus PACS above 4 of 4.
PACS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $45.9 | 4.5% above |
| 20 week MA | $45.2 | 6.3% above |
| 50 week MA | $39.7 | 21% above |
| 100 week MA | $26.2 | 84% above |
PACS is in an uptrend: it's above all four of its weekly moving averages, and 84% above its 100-week average.
CIFR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.92 | $9.95 | +0.3% |
| 2021 | $9.95 | $5.21 | -48% |
| 2022 | $5.21 | $0.54 | -90% |
| 2023 | $0.54 | $4.13 | +665% |
| 2024 | $4.13 | $4.86 | +18% |
| 2025 | $4.86 | $15.2 | +213% |
| 2026 YTD | $15.2 | $7.15 | -53% |
CIFR's yearly returns have swung widely, from +665% in 2023 to −90% in 2022. It's down 53% so far in 2026.
PACS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $24.0 | $13.0 | -46% |
| 2025 | $13.0 | $38.1 | +193% |
| 2026 YTD | $38.1 | $48.0 | +26% |
PACS has the edge over CIFR on returns for 2026, with the stronger performance.